Following the unveiling of a new British studio run by gastroenterologists the use of this drug could increase coronavirus infection risk e impulse the appearance of new varieties.
Sebastián Salguero Cantor
Revista Medicina y Salud Pública
Infliximab is a potent drug employed in treating patients that include patients with Crohn’s disease and ulcerative colitis. For this reason, this medicine will increase the risk of coronavirus infection and may develop new variants according to experts.
Patients using infliximab should be monitored while receiving the vaccine against COVID-19
Approximately millions of people all over the world are receiving treatment with this drug. The pharmacy belongs to a class of medicines that are called inhibitors of tumor necrosis and reduce the immune protection through the vaccine against neonatal, influenza and viral hepatitis.
The study Duidelheid IBD in which 6,932 patients with some form of intestinal inflammatory arthritis were involved, less than the number of patients treated with Infliximab presenting detectable antiseptics during SARS-CoV-2 infection.
“The antitrust inquiry has raised the possibility that these individuals will not develop a protection through covid-19 and will be accompanied by a mayor’s risk of reinfection”: Tariq Ahmad, director of the studio.
Conclusions of the study and advertisement by the experts
Investigators conclude that a more debilitating humanitarian response does not automatically translate into a mayor’s risk of infection. Without embarrassment, it was suggested that patients may be more susceptible to developing COVID-19 persistence and chronic the virus colonization and narcissism.
Information from the Sinc Agency